Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 11, 2005, Pages 1789-1801

  Benedict, Ágnes ^a   Brown, Ruth E ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Advanced breast cancer; Cost effectiveness; Endocrine therapies

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; EXEMESTANE; FLUVESTRANT; LETROZOLE; MEGESTROL; TAMOXIFEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HUMAN; KAPLAN MEIER METHOD; LIFE EXPECTANCY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HEALTH CARE RATIONING; HEALTH EXPENDITURES; HUMANS; MEGESTROL; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 25444501847     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.11.1789     Document Type: Review

References (35)

1. LOVE SM, MCGUIGAN KA, CHAP L: The Revlon/UCLA Breast Center practice guidelines for the treatment of breast disease. Cancer J. Sci. Am. (1996) 2(1):2.
2. GOSS PE: Emerging role of aromatase inhibitors in the adjuvant setting. Am. J. Clin. Oncol. (2003) 26(4):S27-S33.
3. LISTER-SHARP D, MCDONAGH MS, KHAN KS, KLEIJNEN J: A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol. Assess. (2000) 4(17):1-113.
4. LEWIS R, BAGNALL AM, KING S et al.: The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. Health Technol. Assess. (2002) 6(14):1-269.
5. JONES L, HAWKINS N, WESTWOOD M, WRIGHT K, RICHARDSON G, RIEMSMA R: Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol. Assess. (2004) 8(5):iii, xiii-xvi, 1-143.
6. SCHULMAN KA, STADTMAUER EA, REED SD et al.: Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplant. (2003) 31(3):205-210.
7. ELKIN EB, WEINSTEIN MC, WINER EP, KUNTZ KM, SCHNITT SJ, WEEKS JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. (2004) 22(5):854-863.
8. MARTIN SC, GAGNON DD, ZHANG L, BOKEMEYER C, VAN MARWIJK KOOY M, VAN HOUT B: Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics (2003) 21(16): 1153-1169.
9. VERMA S, ILERSICH AL: Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Oncologist (2003) 8(3):232-240.
10. LI N, VAN AGTHOVEN M, WILLEMSE P, UYL-DE GROOT C: A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer. Anticancer Drugs (2001) 12(6):533-540.
11. SAINSBURY R: Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br. J. Cancer (2004) 90(9):1733-1739.
12. ROSE C: A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am. J. Clin. Oncol. (2003) 26(4):S9-S16.
13. THOMAS R: Examining quality of life issues in relation to endocrine therapy for breast cancer. Am. J. Clin. Oncol. (2003) 26(4):S40-S44.
14. DRUMMOND M, O'BRIEN B, STODDART G, TORRANCE G: Methods for the economic evaluation of health care programmes (second edn). Oxford Medical Publications, Oxford (1997).
15. MARCHETTI M, LIBERATO N, BAROSI G: First-line therapy for advanced breast cancer: cost-effectiveness of anastrozole versus tamoxifen. Value in Health (2002) 5(6):443 (Abstr.).
16. HILLNER BE, RADICE D: Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer (2001) 91(3):484-489.
17. VERMA S, ROCCHI A: Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer (2003) 11(11):728-734.
18. DRANITSARIS G, VERMA S, TRUDEAU M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. Oncol. (2003) 26(3):289-296.
19. DRANITSARIS G, LEUNG P, MATHER J, OZA A: Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs (2000) 11(7):591-601.
20. GOLD MR, SIEGEL JE, RUSSELL LB, WEINSTEIN MC: Cost-Effectiveness in Health and Medicine. Oxford University Press, Oxford (1996).
21. NUIJTEN M, MEESTER L, WAIBEL F, WAIT S: Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics (1999) 16(4):379-397.
22. NUIJTEN M, MCCORMICK J, WAIBEL F et al.: Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value in Health (2000) 3:31-39.
23. DRUMMOND M, THOMPSON E, HOWELL A et al.: Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. J. Med. Econ. (1999) 2:33-43.
24. SIMONS WR, JONES D, BUZDAR A: Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin. Ther. (2003) 25(11):2972-2987.
25. LINDGREN P, JONSSON B, REDAELLI A, RADICE D: Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics (2002) 20(2):101-108.
26. KARNON J, JONES T: A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. Pharmacoeconomics (2003) 21(7):513-525.
27. MARCHETTI M, CARUGGI M, COLOMBO G: Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin. Ther. (2004) 26(9):1546-1561.
28. KARNON J, JOHNSTON SR, JONES T, GLENDENNING A: A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann. Oncol. (2003) 14(11):1629-1633.
29. DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. (1998) 16(2):453-461.
30. SAINSBURY R: Author's reply. Aromatase inhibitors in advanced breast cancer: there are efficacy differences. Br. J. Cancer (2005) 92(6):1175-1176.
31. BENEDICT Á, HUTTON J: Piglet's footpath in the snow, or a trap for unwary Heffalumps: derivation of values for a cost-effectiveness threshold. Paper presented at HESG Conference, Glasgow (2004).
32. FRICKE FU, QUEDNAU K, PIRK O: A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients in Germany. Value in Health (2002) 5(6):443-463.
33. + advanced breast cancer: a UK perspective oral presentation at European Breast Cancer Conference (2002). Eur. J. Cancer (2002) 38(Suppl. 3):S68 (Abstr. 116).
34. SIMONS WR, BASSI R, KEMP R, MACKEY JR: Cost-effectiveness analysis of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: a Canadian perspective. Oral presentation at World Conference on Breast Cancer, 2002.
35. RYAN J, HIRSCH M, KINGHT H: Cost-utility analysis of fluvestrant compared with exemestane in the treatment of postmenopausal women with advanced breast cancer after progression on antioestrogen therapy. Poster presented at the European ISPOR meeting, 2004, Hamburg, Germany.